Traditionally, Streptococcus pneumoniae is identified in the laboratory by demonstrating susceptibility to optochin. Between 1992 and 1998, 4 pneumococcal isolates exhibiting optochin resistance were recovered from patients at Children's National Medical Center. Three of the 4 isolates consisted of mixed populations of optochin-resistant and -susceptible organisms. Both subpopulations had identical antibiograms, serotypes, and restriction fragment profiles. The other isolate was uniformly resistant to optochin. Resistant strains had MICs of optochin 4-30-fold higher than susceptible strains, belonged to different serotypes, and had dissimilar restriction fragment profiles, indicating clonal unrelatedness. Resistance arose from single point mutations in either the a-subunit (W206S) or the c-subunit (G20S, M23I, and A49T) of H + -ATPase. There is speculation of a possible association between exposure to antimalarial drugs and evolution of optochin resistance. a-Hemolytic streptococci resistant to optochin, particularly invasive isolates, should be tested for bile solubility or with an S. pneumoniae DNA probe before identification as viridans streptococci.
twentieth century as a chemotherapeutic agent for the treatment of lobar pneumonia. However, serious side effects coupled with treatment failures quickly terminated the therapeutic use of this agent [5] . Although optochin susceptibility was first described for differentiating pneumococci from other a-hemolytic streptococci in 1915 [6] , the test was virtually unused by laboratories until the mid-1950s [7] [8] [9] . During the first 30 years of its use, there were no reports of optochin-resistant pneumococci. Since then, there have been sporadic reports of optochin-resistant pneumococci [10] [11] [12] . Investigators from Spain have cloned, sequenced, and characterized H ϩ -ATPase c-subunit as the gene encoding the optochin determinant [13] .
In the United States, only 2 optochin-resistant strains have been reported. We reported the first isolate in 1997 from Washington, DC [14] , and Borek et al. [15] reported another from Chicago later that year. We since have recovered 3 additional optochin-resistant strains. The purpose of this communication is to report our characterization of the optochin resistance phenotype of these strains and to alert physicians and clinical microbiologists to the existence of these strains in the community.
Materials and Methods
Patients and strains. From 1 June 1992 through 31 May 1998, 587 pneumococcal isolates were recovered from ordinarily sterile body sites of patients treated at Children's National Medical Center (Washington, DC). Three (0.5%) isolates were either uniformly resistant to optochin (strain 310) or consisted of mixed populations of optochin-susceptible and -resistant colonies (strains 606a and 654; figure 1 ). An additional isolate exhibiting optochin-resistant variants (strain HV109) was recovered from the nasopharynx of a patient during a study that investigated the prevalence of penicillinresistant S. pneumoniae colonization in human immunodeficiency virus-infected children. Isolates with optochin-resistant variants formed distinct colonies within the 14-mm diameter inhibitory zone that differentiates optochin susceptibility from resistance. Subcultures of these colonies exhibited uniform resistance to optochin. We used 2 optochin-susceptible clinical isolates and an unencapsulated reference strain (R6) as controls. Table 1 shows the characteristics of the study isolates.
Antibiotic susceptibility testing. MICs of optochin and several antimicrobial agents were determined by the agar dilution method. Bacterial suspensions were prepared in 0.9% NaCl from overnight cultures on 5% sheep blood agar and were adjusted to match the 0.5 McFarland turbidity standard. Suspensions were inoculated onto Mueller-Hinton agar containing 3% lysed horse blood and varying concentrations of optochin or selected antimicrobial agents. Cultures were incubated at 35ЊC for 20-24 h in a 5% CO 2 atmosphere. The MIC was defined as the lowest concentration of optochin or antimicrobial agent that inhibited visible growth of the isolate.
Optochin susceptibility test by disk diffusion method. Optochin disks (6 mm; Becton Dickinson Microbiology Systems) were applied to trypticase soy agar plates with 5% sheep blood streaked with the organism being tested. After overnight incubation at 35ЊC in a 5% CO 2 atmosphere, inhibitory zones around the disk were measured. Isolates displaying zones у14 mm in diameter were identified as S. pneumoniae. Isolates displaying zones !14 mm were tested for bile solubility.
Bile solubility. Heavy bacterial suspensions (1 mL) matching the 2.0 McFarland turbidity standard were prepared in normal saline from overnight 5% sheep blood agar cultures. The suspensions were divided into 2 tubes. Deoxycholate reagent (2%; 0.5 mL; Becton Dickinson Microbiology Systems) was added to one tube, and normal saline (0.5 mL) was added to the other. Tubes were incubated at room temperature for 15 min. Complete clearing of the suspension in the deoxycholate tube was indicative of S. pneumoniae.
Serotyping. Serotyping was done with the Quellung (Neufeld) reaction (capsular swelling) test.
Genomic DNA analysis. Preparation of agarose plugs containing genomic DNA and analysis by pulsed-field gel electrophoresis (PFGE) after digestion with SmaI were done as described elsewhere [16] .
Polymerase chain reaction (PCR). Based on the sequence reported by Fenoll et al. [13] , we designed primers 663 (5 -TCGA-AAAGTGGATCAACAACTATCC-3 ) and 1016 (5 -TGGGAAA-GAAGAAGTAACAAACTCG-3 ) to amplify the DNA fragment encoding the ATPase c-subunit from the pneumococcal strains examined in this study. The components of the amplification mixtures (100 mL) were as follows: 5 U of Pfu DNA polymerase (Stratagene), 1ϫ reaction buffer provided by the manufacturer, 20 mM each of the 4 dNTPs, 100 ng of DNA, and 250 ng of each primer. Amplification was done in a thermal cycler (model 9600; Perkin-Elmer Instruments). After an initial 2-min incubation at 95ЊC, the mixture was subjected to 30 cycles of amplification under the following conditions: 95ЊC, 1 min; 58ЊC, 1 min; 72ЊC, 2 min; and a final 10-min runoff at 72ЊC. After purification, the PCR product was ligated into pCR-Blunt vector (Invitrogen), and the ligation products were transformed into Escherichia coli TOP10 competent cells. E. coli transformants were selected on LB agar containing 50 mg/mL kanamycin.
DNA sequence analysis. Sequencing was done with the dideoxynucleotide chain-termination method by using modified T7 DNA polymerase and [a-
35
S]deoxyadenosine triphosphate for labeling. For all clones, both strands of inserts were sequenced. We used the MacVector 7.0 sequence analysis package (Genetics Computer Group) to assemble, edit, and analyze the results.
Genetic transformation of S. pneumoniae. S. pneumoniae was genetically transformed according to a procedure described by Lacks [17] , with the following modification: growth medium was supplemented with 0.2% sucrose, but yeast extract was omitted. Transformants were selected on Mueller-Hinton agar plates containing 5 mg/mL optochin and enriched with 3% defibrinated lysed horse blood.
Nucleotide sequence accession numbers.
The nucleotide sequence data were deposited in the GenBank database under accession numbers AF334388-AF334397.
Results
All optochin-resistant S. pneumoniae isolates were a-hemolytic and bile soluble, exhibited typical colony morphology, and produced pneumococcal capsular polysaccharide. Optochin MICs were 4-30-fold higher in optochin-resistant than in optochin-susceptible strains (table 1) . No relationship between resistance to optochin and other antimicrobial agents tested was detected. For isolates that yielded optochin-resistant variants, both optochin-susceptible and -resistant colonies were bile soluble, demonstrated identical antimicrobial susceptibility profiles, and were of identical serotypes (table 1). The 4 optochin-resistant isolates belonged to serotypes 6B, 9V, 14, and 19F, all common serotypes in the Washington, DC, region [18] . PFGE analysis of the DNA from the optochin-resistant isolates after digestion with restriction endonuclease SmaI disclosed that the isolates were clonally unrelated. However, in isolates with optochin-resistant variants, comparison of PFGE of optochin-susceptible and -resistant colonies revealed identical profiles (figure 2).
We compared the ATPase c-subunit amino acid sequences from optochin-susceptible and -resistant strains to ascertain whether optochin resistance was associated with any amino acid changes [13] . For isolates exhibiting optochin-resistant variants, sequence analyses were performed on both susceptible and resistant colonies. All optochin-susceptible strains and, surprisingly, 1 resistant strain (HV109/R) possessed identical ATPase c-subunit amino acid sequences. The amino acid sequences in the 3 remaining optochin-resistant strains differed from the susceptible strains by only 1 amino acid. Specifically, isoleucine replaced methionine at residue 23 in resistant strain 310, threonine replaced alanine at residue 49 in resistant strain 606a/R, and serine replaced glycine at residue 20 in resistant strain 654/ R (figure 3).
Our finding that the optochin-susceptible and -resistant variants of isolate HV109 had identical ATPase c-subunit nucleotide sequences suggested that mutations within a different ATPase subunit might also confer optochin resistance. By using primers 961 (5 -TTTGGGAATATCTTTGCAGGAGAG-3 ) and 1791 (5 -TGCGACTTGCTTGATTTGATCC-3 ), we cloned and sequenced the remaining portion of the ATPase a-subunit, the ATPase b-subunit, and part of the ATPase x-subunit from both Genetic transformation experiments confirmed that each of the individual amino acid changes described conferred optochin resistance. Experiments were done using the optochin-susceptible strain HV109/S as recipient and plasmid DNA encoding either the ATPase a-or c-subunit from the optochin-resistant strains ligated into pCR-Blunt vector as donor. Plasmids were linearized by digestion with AspI restriction endonuclease before transformation. AspI cleaved at only one site in the cloning vector and did not cleave the donor DNA insert. Encapsulated S. pneumoniae HV109/S was selected as the transformation recipient because its DNA sequence differed from each of the optochin-resistant strains by only 1 base in the region of interest. In addition, preliminary tests with the HV109/S strain showed that it could be reproducibly transformed by using DNA from a streptomycin-resistant pneumococcus. Two transformants from each experiment were selected and tested for susceptibility to optochin. Results showed identical optochin MICs between the transformants and the original optochinresistant donors. Sequence analysis of the transformants confirmed the expected amino acid changes.
Discussion
Despite the development of newer techniques (e.g., use of DNA probes and PCR) [19, 20] , the optochin susceptibility test remains the primary and, in some cases, the only method used by clinical microbiology laboratories to differentiate S. pneumoniae from other viridans streptococci [4, 21] . Strains displaying a growth inhibitory zone у14 mm in diameter around a 6-mm optochin disk are identified as S. pneumoniae. Those producing zones !14 mm in diameter are questionable pneumococci and should be tested further to determine whether they are bile soluble [3] . When there is no inhibitory zone around the optochin disk, laboratories routinely identify isolates as viridans streptococci and do not perform bile solubility testing [21] .
Although S. pneumoniae was considered universally susceptible to optochin for almost 30 years after the optochin susceptibility test was introduced, a number of isolates have been reported as optochin resistant in recent years. In 1987, Kontiainen and Sivonen [10] were the first to report pneumococci that exhibited an optochin-resistant subpopulation. A similar phenomenon was described a year later by Phillips et al. [11] . Muñoz et al. [12] reported that 10 (1.2%) of 814 pneumococcal isolates submitted to their reference center in 1987-1988 contained optochinresistant variants. Three of our isolates also produced a mixed population of optochin-susceptible and -resistant colonies. Predominance of optochin-resistant variants can easily lead to misidentification of isolates as viridans streptococci. One of our isolates (strain 310; figure 1 ) and the isolate from Chicago reported by Borek et al. [15] were uniformly resistant to optochin. Investigators from Spain recently identified a gene responsible for the optochin susceptibility/resistance phenotype [13] . They found that point mutations in amino acid residues 48, 49, or 50 of the H ϩ -ATPase c-subunit confer optochin resistance. H ϩ -ATPase is a membrane-bound multimeric enzyme com- plex responsible for proton translocation across plasma membranes. This enzyme is an F 0 F 1 class ion transport ATPase found in bacteria, mitochondria, and chloroplasts. The F 0 sector of the complex comprises membrane-embedded protein subunits that translocate hydrogen ions, while the F 1 component of the complex contains the catalytic subunit for ATP hydrolysis and synthesis [22] . We compared sequences of ATPase a-and c-subunits from various optochin-resistant and -susceptible pneumococcal strains and found that several single amino acid mutations segregate with optochin resistance (figures 3 and 4). Site-specific mutagenesis of an optochin-susceptible S. pneumoniae strain at single amino acid residues corresponding to changes in either the a-subunit (Trp206Ser) or the c-subunit (Gly20Ser, Met23Ile, and Ala49Thr) conferred optochin resistance. These results confirm that the single amino acid change observed in our clinical isolates is responsible for optochin resistance. Of note, 3 of the optochin-resistant pneumococcal isolates had mutations at sites different than those reported from Spain [13] . Moreover, this is the first report of a mutation affecting the ATPase a-subunit. Our other 2 optochin-resistant isolates had mutations (Gly20Ser and Met23Ile) within the a-helix 1 transmembrane domain of the ATPase c-subunit ( figure 5 ). All the Spanish mutations (from clinical isolates or laboratory-generated mutants after selection on plates containing optochin) had mutations corresponding to the a-helix 2 domain of the ATPase c-subunit [13] . However, in a related study, laboratory-generated pneumococcal mutants resistant to quinine had mutations at the same site on a-helix 1 as our optochin-resistant clinical isolates [26] . These quinine-resistant mutants, which also exhibited cross-resistance to optochin, were obtained by spreading R6 cells on plates containing quinine. An optochin-resistant pneumococcal clinical isolate with a mutation (Gly14Ser) corresponding to the transmembrane a-helix 1 was described recently in France [27] .
Oligomeric complexity of ATPases varies among different organisms; however, subunits involved in H ϩ translocation and ATP synthesis show remarkable amino acid homology and structural similarity. On this basis, it is believed that the enzymatic mechanism is the same in all species. The ATPase from E. coli is one of the best-studied models of a membrane-bound enzyme complex. Although all 3 subunits (a, b, and c) are required for a functional F 0 component, it appears that only the a-and csubunits are directly involved in H ϩ translocation. Structural and genetic analyses show that certain amino acid residues in the transmembrane domains of the model are essential for H ϩ translocation across the plasma membrane [22] .
To understand the structural relationship between a single amino acid mutation and the mechanism of optochin resistance in S. pneumoniae, we compared the sequences of the a-and csubunits of our strains with the corresponding E. coli sequences. We compiled table 2 and figure 5 by use of Clustal-W amino acid alignments to the E. coli ATPase. This putative model shows the structural relationships between mutations that confer optochin (or both optochin and quinine) resistance and amino acid residues that are essential to H ϩ translocation. By analogy to the E. coli enzyme, the putative S. pneumoniae model for the F 0 portion of ATPase consists of a membrane-embedded cylinder made up of 10-12 c-subunits with 1 a-subunit positioned within the membrane matrix on the outer surface of the cylinder. Individual c-subunits consist of 2 transmembrane ahelices joined by a short conserved cytoplasmic loop. The cylinder structure is stabilized by hydrogen bond interactions between the backbone carbonyl of valine 15 in a-helix 1 and the carboxyl side chain of glutamate 52 in a-helix 2 of an adjacent c-subunit (and possibly between valine 48 in a-helix 2 and glutamate 19 in a-helix 1; figure 5 ). The protein cylinder acts as a rotor embedded in the membrane. The proton pathway through the membrane is thought to be formed by an opening of the interface between adjacent c-subunits by swiveling of amino acid residues identical to those of the E. coli sequence; orange circles, residues that are similar in structure; open circles, residues unique to S. pneumoniae enzyme. Residues that are essential to stabilizing adjacent c-subunits in the cylinder structure (V15 with E52 and possibly V48 with E19) or essential to H ϩ translocation across the membrane (E52 in c-subunit and R170, E179, and S210 in a-subunit) are indicated by residue no. in sequence. Residues within the cytoplasmic loop of the c-subunit and E160 in the a-subunit are highly conserved among different species. Amino acid mutations that are responsible for optochin resistance are marked with red and show residue no., followed by amino acid mutation that confers resistance (G14S, G20S, M23I, V48F, A49T, and F50L in c-subunit and W206S in a-subunit). Figure is based on the work of Miller et al. [23] , Hatch et al. [24] , Fillingame et al. [25] , and de la Campa et al. [26] . helix 1, thus allowing a hydrogen from the protonated glutamate 52 carboxyl side chain on helix 2 to transfer to the asubunit on the outer surface of the cylinder [33] .
In our putative model, all amino acid mutations that confer optochin resistance are located within those regions of helices that transverse the membrane. No mutations were observed in amino acids thought to be essential to hydrogen transport. Although the molecular mechanism of exactly how optochin interacts with the F 0 portion of ATPase is still unresolved, we believe that in the presence of optochin the proton-translocating subunits of ATPase are perturbed in such a way that the H Critical for conducting H ions in transport mechanism in E. coli [29] iae, amino acid changes within the a-or c-subunits prevent optochin from disrupting the H ϩ transport path. The origin of optochin resistance in S. pneumoniae is unclear. S. pneumoniae is a naturally transformable microorganism, and, in many cases, resistance to certain antibiotics has been ascribed to acquisition of either free DNA from other species followed by DNA recombination or by the transfer of conjugative transposons encoding antimicrobial resistance genes [34] . Resistance due to single point mutations is less common but has been demonstrated for high-level trimethoprim resistance [35] and low-level fluoroquinolone resistance [36] . Our findings indicate that optochin resistance in S. pneumoniae is a result of point mutations in either the ATPase a-or c-subunit. This hypothesis is strongly supported by the findings from the 3 isolates with optochin-resistant variants. In those mixed isolates, the identical PFGE profile, serotype, and antibiogram, together with sequence analysis and transformation experiments, indicate that resistant variants originated from susceptible cells by single point mutations.
It is intriguing that the mutations at positions 20 and 23 of the c-subunit of our clinical isolates are in the same position as the mutations observed in laboratory-derived pneumococcal mutants resistant to quinine. The presence of antibacterials in a given environment provides selective pressure that results in the enrichment of resistant strains. Although optochin is used only as a diagnostic tool in clinical microbiology laboratories, similar compounds such as quinine and mefloquine are widely used for treatment and prophylaxis against malaria. Each year several thousand American or foreign travelers arrive in the Washington, DC, metropolitan area from malaria-endemic areas, and imported malaria is not uncommon [37] . Even though none of our patients with optochin-resistant S. pneumoniae was treated for malaria or had a travel history to a malaria-endemic area, possible acquisition of these unique pneumococcal strains from persons who did seems plausible and cannot be ruled out. Further epidemiological studies to investigate the incidence of optochin resistance in S. pneumoniae in malaria-endemic areas are needed to clarify a possible role of quinine and other similar analogues in the evolution of optochin resistance.
Misidentification of optochin-resistant S. pneumoniae as a viridans streptococcus can have significant implications for the treatment and outcome of patients. We recommend that at a minimum invasive a-hemolytic streptococci resistant to optochin be checked for lack of bile solubility before being identified as viridans streptococci. Even though bile-insoluble pneumococcal isolates have been reported [21] , the addition of this latter test should minimize the possibility of misidentification. A commercial DNA probe test is of higher sensitivity and specificity than standard tests [19] but may be too expensive for routine use. However, it should be considered for evaluation of isolates with a typical colony morphology for S. pneumoniae that yield questionable results by other methods.
